A retrospective cohort study examined the association between tirzepatide and semaglutide use in adults with asthma and type 2 diabetes. The study utilized data from the TriNetX US Collaborative Network, including patients who initiated tirzepatide or semaglutide between June 01, 2022, and December 31, 2024, with a follow-up period ending on December 1, 2025.
Key Clinical Findings
The primary outcome measured the time to first asthma exacerbation over a 12-month follow-up. Propensity score matching was employed to balance baseline characteristics. After 1:1 matching, 8176 patients were included in each group. The risk of asthma exacerbation was similar between the two groups. Secondary outcomes assessed systemic corticosteroid and short-acting beta-agonist (SABA) use. Tirzepatide was associated with a lower risk of SABA use and a similar risk of systemic corticosteroid use compared to semaglutide.
Conclusion
This research indicates no difference in the risk of asthma exacerbation between tirzepatide and semaglutide in patients with asthma and type 2 diabetes. Further investigation through randomized controlled trials is recommended to determine the potential role of GLP-1 Receptor Agonist-based therapies in this patient population.”} p>